Visit KQAK 105.7
Visit The Peak 104.1
Visit 95.7 The Ranch
Visit 92.5 The Ticket
Visit KBNW 104.5AM AND 1340AM
Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MacroGenics, Inc. - Common Stock (NQ:MGNX)

3.370 +0.060 (+1.81%)
Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MacroGenics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations
TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced... 
Via MediaOutReach
Topics Economy
News headline image
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million 
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer 
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
Synergy CHC (NASDAQ: SNYR) Taps Coca-Cola Exec to Accelerate Global Expansion of “FOCUSfactor®” Energy Drink – More Stocks Moving Inside
Via AB Newswire
News headline image
Power Metallic (TSXV: PNPN) (OTCQB: PNPNF) Positioned for Critical Minerals Breakout Following Acquisition – More Stocks Inside
Via AB Newswire
News headline image
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Date of First Quarter 2025 Financial Results
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Leadership Transition
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
From TerSera Therapeutics LLC
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.